We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Calliditas Therapeutics AB (CALTX) NPV

Sell:206.20 SEK Buy:206.40 SEK Change: No change
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Takeover

Calliditas Therapeutics AB NPV

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Jun 2024)

The boards of Calliditas Therapeutics AB and Asahi Kasei Corporation recently announced the terms of a takeover. Under the terms of the takeover you have been offered SEK208.00 for each share held.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Sell shares in the offer – Act by noon on Tuesday 27 August 2024

 

Will I receive any cash proceeds in Swedish Krona?

 

No, cash from any successful tender will be converted to Pound Sterling by CREST, the UK settlement system, prior to receipt and credited to your account.

 

Full details of this event will be sent to qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:206.20 SEK
Buy:206.40 SEK
Change: No change
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Takeover

Calliditas Therapeutics AB NPV

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Jun 2024)

The boards of Calliditas Therapeutics AB and Asahi Kasei Corporation recently announced the terms of a takeover. Under the terms of the takeover you have been offered SEK208.00 for each share held.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Sell shares in the offer – Act by noon on Tuesday 27 August 2024

 

Will I receive any cash proceeds in Swedish Krona?

 

No, cash from any successful tender will be converted to Pound Sterling by CREST, the UK settlement system, prior to receipt and credited to your account.

 

Full details of this event will be sent to qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:206.20 SEK
Buy:206.40 SEK
Change: No change
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Takeover

Calliditas Therapeutics AB NPV

Type:
Takeover
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Jun 2024)

The boards of Calliditas Therapeutics AB and Asahi Kasei Corporation recently announced the terms of a takeover. Under the terms of the takeover you have been offered SEK208.00 for each share held.

 

If you don’t want to sell any shares, you don’t need to do anything. Depending on the level of acceptance the offeror may choose to delist or compulsorily acquire the remaining shares at a later date.

 

Sell shares in the offer – Act by noon on Tuesday 27 August 2024

 

Will I receive any cash proceeds in Swedish Krona?

 

No, cash from any successful tender will be converted to Pound Sterling by CREST, the UK settlement system, prior to receipt and credited to your account.

 

Full details of this event will be sent to qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Contact details

Address:
D5, Kungsbron 1,
STOCKHOLM
111 22
Sweden
Telephone:
+46 (8) 4113005
Website:
https://www.calliditas.se/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CALTX
ISIN:
SE0010441584
Market cap:
12.36 billion SEK
Shares in issue:
53.67 million
Sector:
Pharmaceuticals
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Renee Aguiar-Lucander
    Chief Executive Officer
  • Fredrik Johansson
    Chief Financial Officer
  • Maria Tornsen
    President, North America
  • Frank Bringstrup
    Vice President - Regulatory Affairs
  • Brian Gorman
    Group General Counsel
  • Sandra Frithiof
    Head of Human Resources
  • Richard Philipson
    Chief Medical Officer
  • Lars Stubberud
    Head of Technical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.